Progestin

Progestin
Drug class
Medroxyprogesterone acetate (Provera, Depo-Provera), a progesterone derivative and one of the most widely used progestins.
Class identifiers
Synonyms Synthetic progestogens
Use Hormonal birth control, hormone therapy, gynecological disorders, fertility and pregnancy support, sex hormone suppression, others
ATC code G03
Biological target Progesterone receptors (PR-A, PR-B, PR-C)
Chemical class Steroids (pregnanes, norpregnanes, androstanes, estranes)
Clinical data
Drugs.com Drug Classes
External links
MeSH D011372
In Wikidata

A progestin is a type of medication which is used most commonly in hormonal birth control and menopausal hormone therapy.[1] They can also be used in the treatment of gynecological conditions, to support fertility and pregnancy, to lower sex hormone levels for various purposes, and for other indications.[1] Progestins are used alone or in combination with estrogens.[1] They are available in a wide variety of formulations and for use by many different routes of administration.[1]

Side effects of progestins include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and changes in liver protein production among others.[1][2] Other side effects of progestins include an increased risk of breast cancer, cardiovascular disease, and blood clots.[2] At high dosages, progestins can cause low sex hormone levels and associated side effects like sexual dysfunction and an increased risk of bone fractures.[3]

Progestins are synthetic progestogens and have similar effects to those of the natural hormone progesterone.[1] They act as agonists of the progesterone receptor, and have important effects in the female reproductive system (uterus, cervix, and vagina), the breasts, and the brain.[1] In addition, many progestins also have other hormonal activities, such as androgenic, antiandrogenic, estrogenic, glucocorticoid, or antimineralocorticoid activity.[1] They also have antigonadotropic effects and at sufficiently high dosages can strongly suppress sex hormone production.[1] Progestins mediate their contraceptive effects both by inhibiting ovulation and by thickening cervical mucus, thereby preventing fertilization.[4][5] They have functional antiestrogenic effects in certain tissues like the endometrium, and this underlies their use in menopausal hormone therapy.[1]

Progestins were first introduced for medical use in 1939.[6][7][8] They started to be used in birth control in the 1950s.[6] Around 60 progestins have been marketed for clinical use in humans or use in veterinary medicine.[9][10][11][12][13] These progestins can be grouped into different classes and generations.[1][14][15] Progestins are available widely throughout the world and are used in all forms of hormonal birth control and in most menopausal hormone therapy regimens.[9][10][12][11][1]

Medical uses

Birth control

Progestins are used in a variety of different forms of hormonal birth control for women, including combined estrogen and progestogen forms like combined oral contraceptive pills, combined contraceptive patches, combined contraceptive vaginal rings, and combined injectable contraceptives; and progestogen-only forms like progestogen-only contraceptive pills ("mini-pills"), progestogen-only emergency contraceptive pills ("day-after pills"), progestogen-only contraceptive implants, progestogen-only intrauterine devices, progestogen-only contraceptive vaginal rings, and progestogen-only injectable contraceptives.[16][17][18][19]

Progestins mediate their contraceptive effects by multiple mechanisms, including prevention of ovulation via their antigonadotropic effects; thickening of cervical mucus, making the cervix largely impenetrable to sperm; preventing capacitation of sperm due to changes in cervical fluid, thereby making sperm unable to penetrate the ovum; and atrophic changes in the endometrium, making the endometrium unsuitable for implantation.[20][21][22][23] They may also decrease tubal motility and ciliary action.[23]

Combined androgen and progestogen birth control methods for men have been extensively studied but have yet to be approved or marketed.[24]

Hormone therapy

Progestins are commonly used as a component of menopausal hormone therapy in women to prevent endometrial hyperplasia and increased risk of endometrial cancer from unopposed estrogen therapy. They are also used in transgender hormone therapy, including in both feminizing hormone therapy for transgender women (e.g., cyproterone acetate and medroxyprogesterone acetate to help suppress testosterone levels) and masculinizing hormone therapy in transgender men (e.g., medroxyprogesterone acetate to help suppress menses).

Certain progestins, including megestrol acetate, medroxyprogesterone acetate, cyproterone acetate, and chlormadinone acetate have been used to reduce hot flashes in men with prostate cancer.[25][26][27]

Gynecological disorders

Progestins are used to treat gynecological disorders such as secondary amenorrhea, dysfunctional uterine bleeding, and endometriosis.[17][18] In a normal menstrual cycle, declining levels of progesterone triggers menstruation. Norethisterone acetate and medroxyprogesterone acetate may be used to artificially induce progestogen-associated breakthrough bleeding.[28]

Progestogens are also used to treat benign breast disorders.[29][30] They are associated not only with a reduction in breast pain, but also a decrease in breast cell proliferation, a decrease in breast gland size, and a disappearance of breast nodularity.[29][30][31] Progestogens that have been used for such purposes include topical progesterone, dydrogesterone, promegestone, lynestrenol, medroxyprogesterone acetate, dienogest, and medrogestone.[29][30][32][31]

Gynecological cancers

Progestins were first found to be effective at high dosages in the treatment of endometrial hyperplasia and endometrial cancer in 1959.[33][34][35] Subsequently, high-dosage gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone acetate, and megestrol acetate were approved for the treatment of endometrial cancer.[36][37][38]

Progestins, such as megestrol acetate and medroxyprogesterone acetate, are effective at high dosages in the treatment of advanced postmenopausal breast cancer.[39][40] They have been extensively evaluated as a second-line therapy for this indication.[39] However, they produce various side effects, such as dyspnea, weight gain, vaginal bleeding, nausea, fluid retention, hypertension, thrombophlebitis, and thromboembolic complications.[39][40] In addition, megestrol acetate has been found to be significantly inferior to aromatase inhibitors in the treatment of breast cancer, and in relation to this, progestins have been moved down in the sequential therapy of the disease.[39] Megestrol acetate is the only Food and Drug Administration-approved progestin for breast cancer.[39] The mechanism of action of progestins in the treatment of breast cancer is unknown, but may be related to their functional antiestrogenic and/or antigonadotropic effects.[39]

Fertility and pregnancy

Progestogens are used in fertility medicine for women. For example, progesterone (or sometimes dydrogesterone or hydroxyprogesterone caproate) is used for luteal support in in-vitro fertilization protocols.[41]

Certain progestins are used to support pregnancy, including hydroxyprogesterone caproate, dydrogesterone, and allylestrenol. They are used questionably for treatment of recurrent pregnancy loss and for prevention of preterm birth in pregnant women with a history of at least one spontaneous preterm birth.[41]

Sex-hormone suppression

Certain progestins are used at high dosages as antigonadotropins to suppress sex hormone production and levels as a form of medical castration for a variety of androgen and estrogen-dependent conditions. Examples of indications include treating prostate cancer, benign prostatic hyperplasia, blocking precocious puberty and puberty in transgender youth, lowering sex hormone levels in transgender people and reducing libido in men with sexual deviance such as in sex offenders, paraphilias, and hypersexuality. Progestins that have been used for such purposes include allylestrenol, chlormadinone acetate,[42] cyproterone acetate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone acetate,[43] megestrol acetate, and oxendolone.[44] The progestins that have been used to treat prostate cancer include chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, and megestrol acetate.[45][46] However, only chlormadinone acetate and cyproterone acetate have been approved or commonly used for the treatment of prostate cancer.[46]

Some progestins are also antiandrogens, for instance cyproterone acetate, and can be used to treat androgen-dependent conditions like acne and hirsutism in women.

Appetite stimulation

Certain progestins can be used at very high dosages to increase appetite in conditions like cachexia, anorexia, and wasting syndromes. In general, they are used in combination with certain other steroid medications such as dexamethasone. Their effects take several weeks to become apparent, but are relatively long-lived when compared to those of corticosteroids. Furthermore, they are recognized as being the only drugs to increase lean body mass. Megestrol acetate is the lead drug of this class for the management of cachexia, and medroxyprogesterone acetate is also used.[47][48] The mechanism of action of the appetite-related effects of these two drugs is unknown and may not be related to their progestogenic activity.

Available forms

Progestins are available in the form of oral tablets, solutions and suspensions for intramuscular or subcutaneous injection, and a number of other forms (e.g., transdermal patches, vaginal rings, intrauterine devices, subcutaneous implants).

Progestogens marketed for clinical or veterinary use
Generic nameClassBrand name(s)Route(s)LaunchStatusHitsa
Acetomepregenol17α-OHP; EsterDiamolOral1981Available2,400
Algestone acetophenide17α-OHP; Cyclic ketalDeladroxate, othersIM1964Available52,200
Allylestrenol19-NT; EstraneGestanin, othersOral1961Available61,800
Altrenogest19-NT; EstraneRegumate, MatrixVeterinary1980sVeterinary68,400
Anagestone acetate17α-OHP; EsterAnatropinOral1968Discontinued19,500
Chlormadinone acetate17α-OHP; EsterBelara, othersOral1965Available220,000
Chlormethenmadinone acetate17α-OHP; EsterBiogest, AgelinOral1960sDiscontinued328
Cyproterone acetate17α-OHP; EsterAndrocur, DianeOral, IM1973Available461,000
DanazolT; EstraneDanocrineOral1971Available1,610,000
Delmadinone acetate17α-OHP; EsterTardakVeterinary1972Veterinary42,600
Demegestone19-NPLutionexOral1974Discontinued39,000
Desogestrel19-NT; GonaneCerazette, MircetteOral1981Available714,000
Dienogest19-NT; EstraneNatazia, QlairaOral1995Available220,000
DimethisteroneT; EstraneLutagan, SecrosteronOral1959Discontinued43,100
DrospirenoneSPLAngeliq, YasminOral2000Available570,000
DydrogesteroneRPDuphastonOral1961Available225,000
EthisteroneT; EstranePranone, Proluton-COral, sublingual1939Discontinued59,400
Etonogestrel19-NT; GonaneImplanon, NuvaRingImplant, vaginal (ring)1998Available266,000
Etynodiol diacetate19-NT; Estrane; EsterDemulen, othersOral1965Available335,400
Flugestone acetate17α-OHP; EsterChronogestVeterinary1960sVeterinary63,900
Flumedroxone acetate17α-OHP; EsterDemigran, LeomigranOral1960sDiscontinued32,600
Gestodene19-NT; GonaneFemodene, othersOral1987Available186,000
Gestonorone caproate19-NP; EsterDepostat, PrimostatIM1973Available119,000
Gestrinone19-NT; GonaneDimetriose, othersOral1986Available55,300
Haloprogesterone17α-BPProhaloneOral1961Discontinued4,520
Hydroxyprogesterone acetate17α-OHP; EsterProdoxOral1957Discontinued48,300
Hydroxyprogesterone caproate17α-OHP; EsterMakena, ProlutonIM1954Available438,000
Hydroxyprogesterone heptanoate17α-OHP; EsterH.O.P., Lutogil A.P.IM1950sDiscontinued4,950
Levonorgestrel19-NT; GonanePlan B, othersOral, patch, IUD, implant1970Available2,310,000
Lynestrenol19-NT; EstraneExluton, MinistatOral1961Available76,600
Medrogestone17α-MPColproneOral1966Available84,700
Medroxyprogesterone acetate17α-OHP; EsterProvera, Depo-ProveraOral, IM, SC1958Available1,250,000
Megestrol acetate17α-OHP; EsterMegaceOral, IM1963Available510,000
Melengestrol acetate17α-OHP; EsterHeifermax, MGAVeterinary1960sVeterinary81,300
Methenmadinone acetate17α-OHP; EsterSuperlutin, AntigestOral1960sDiscontinued4,800
Nomegestrol acetate19-NP; EsterLutenyl, ZoelyOral1986Available106,000
Norelgestromin19-NT; GonaneEvra, Ortho EvraTransdermal (patch)2002Available83,400
Norethisterone19-NT; EstraneAygestin, Primolut NOral1957Available881,000
Norethisterone acetate19-NT; Estrane; EsterPrimolut-NorOral, transdermal (patch)1964Available348,000
Norethisterone enanthate19-NT; Estrane; EsterNoristerat, NorigestIM1957Available104,000
Noretynodrel19-NT; EstraneEnovidOral1957Discontinued158,000
Norgesterone19-NT; EstraneVestalinOral1960sDiscontinued7,130
Norgestimate19-NT; Gonane; EsterOrtho-Cyclen, SprintecOral1986Available361,000
Norgestomet19-NP; EsterSyncro-Mate BVeterinary1970sVeterinary101,000
Norgestrel19-NT; GonaneOvralOral1966Available319,000
Norgestrienone19-NT; EstraneOgyline, PlanorOral1960sDiscontinued57,300
Normethandrone19-NT; EstraneMetalutinOral1957Available68,100
Norvinisterone19-NT; EstraneNeoprogestin, othersOral1960sDiscontinued22,100
Osaterone acetate17α-OHP; EsterYpozaneVeterinary2007Veterinary87,600
Oxendolone19-NT; EstraneProstetin, RoxenoneIM1981Available36,100
Pentagestrone acetate17α-OHP; EsterGestovis, GestovisterOral1961Discontinued3,440
ProgesteroneP4Prometrium, othersOral, vaginal, IM, others1934Available11,000,000
Proligestone17α-OHP; Cyclic ketalCorvinan, DelvosteronVeterinary1975Veterinary22,100
Promegestone19-NPSurgestoneOral1983Available98,700
Quingestanol acetate19-NT; Estrane; Ester; EtherDemovis, PilominOral1972Discontinued37,700
QuingestroneP4; EtherEnol-LuteovisOral1962Discontinued27,600
Segesterone acetate19-NP; EsterElcometrine, NestoroneImplant, vaginal (ring)2000Available88,900
Tibolone19-NT; EstraneLivial, TibofemOral1988Available247,000
TrengestoneRPRetroneOral1974Discontinued3,520
Trimegestone19-NPLovelle, othersOral2001Available64,500
Footnotes: a = Hits = Google Search hits (as of February 2018). Class: P4 = Progesterone. 17α-OHP = 17α-Hydroxyprogesterone. 17α-MP = 17α-Methylprogesterone. 17α-BP = 17α-Bromoprogesterone. 19-NP = 19-Norprogesterone. RP = Retroprogesterone. T = Testosterone. 19-NT = 19-Nortestosterone. SPL = Spirolactone. Sources: See individual articles. Miscellaneous: Direct link to table.

Contraindications

Contraindications of progestins may include breast cancer and a history of venous thromboembolism among others.

Side effects

Progestogens have relatively few side effects at typical dosages.[49] Side effects of progestins may include tiredness, dysphoria, depression, mood changes, menstrual irregularities, hypomenorrhea, edema, vaginal dryness, vaginal atrophy, headaches, nausea, breast tenderness, decreased libido.[1][2][49] Progestins with androgenic activity, namely 19-nortestosterone derivatives, can also cause acne, hirsutism, seborrhea, voice deepening, changes in liver protein production (e.g., decreased HDL cholesterol, sex hormone-binding globulin), increased appetite, and weight gain, among others.[1][49] Other side effects of progestins include an increased risk of breast cancer, cardiovascular disease, and blood clots, among others.[2] Some of the side effects of progestins are due not to their progestogenic activity but rather due to off-target activities (e.g., androgenic activity, glucocorticoid activity).[1][50] At high dosages, due to their antigonadotropic effects, progestins can cause low sex hormone levels and associated side effects like diminished secondary sexual characteristics, sexual dysfunction (e.g., reduced sex drive and erectile dysfunction), reversible infertility, reduced bone mineral density, and an increased risk of bone fractures, both in men and in premenopausal women.[3]

A 2018 systematic review found no association between progestogen-only contraception and depression in women. However, the systematic review did not use Randomized Placebo-Controlled double blind trials for its review.[51] This is in contrast to other research which found a relationship between hormonal contraceptive use and subsequent prescription antidepressant use.[52]

Overdose

Progestins are relatively safe in acute overdose.

Interactions

Inhibitors and inducers of cytochrome P450 enzymes and other enzymes such as 5α-reductase may interact with progestins.

Pharmacology

Pharmacodynamics

Progestins act by binding to and activating the progesterone receptors (PRs), including the PR-A, PR-B, and PR-C.[1][53][54] Major tissues affected by progestogens include the uterus, cervix, vagina, breasts, and brain.[1] By activating PRs in the hypothalamus and pituitary gland, progestins suppress the secretion of gonadotropins and thereby function as antigonadotropins at sufficiently high dosages.[1] Interaction of progestins with membrane progesterone receptors is less clear.[55][56] Progestins mediate their contraceptive effects in women both by inhibiting ovulation (via their antigonadotropic effects) and by thickening cervical mucus, thereby preventing the possibility of fertilization of the ovum by sperm.[4][5] Progestins have functional antiestrogenic effects in various tissues like the endometrium via activation of the PR, and this underlies their use in menopausal hormone therapy (to prevent unopposed estrogen-induced endometrial hyperplasia and endometrial cancer).[1]

The PRs are induced in the breasts by estrogens, and for this reason, it is assumed that progestogens cannot mediate breast changes in the absence of estrogens.[57]

In addition to their progestogenic activity, many progestins have off-target activities such as androgenic, antiandrogenic, estrogenic, glucocorticoid, or antimineralocorticoid activity.[1][2][50] Such actions can contribute both to their beneficial or desirable effects and to their side effects.[1][2][58]

Pharmacodynamics of progestogens
ProgestogenClassOff-target activitiesRelative binding affinities (%)Refs
ESANAAGCAMPRARERGRMRSHBGCBG
AllylestrenolaEstrane–±–––1000?0?[59][60]
Chlormadinone acetatePregnane––++–67508000
Cyproterone acetatePregnane––+++–90606800
DemegestoneNorpregnane–––––1151051–2??[61][62][63][64]
DesogestrelaGonane–+–±–1000000
DienogestGonane––+––51001000
DrospirenoneSpirolactone––+–+35650623000
DydrogesteroneaPregnane––––±750?????
EthisteroneAndrostane–+–––180000??[63][64]
EtonogestrelGonane–+–±–150200140150
Etynodiola,bEstrane++–––1011–180???[65]
Etynodiol diacetateaEstrane++–––10000??
GestodeneGonane–+–++90–43285027–3897–290400[66]
Gestonorone caproatePregnane–––––???????
Hydroxyprogesterone caproatePregnane––––±???????[67][68][69]
LevonorgestrelGonane–+–––150–1624501–817–75500[66]
LynestrenolaEstrane++–––11300??
MedrogestonePregnane––±––???????
Medroxyprogesterone acetatePregnane–±–+–115–1495029–583–16000[66]
Megestrol acetatePregnane–±++–655030000
Nomegestrol acetateNorpregnane––+––1254206000
NorelgestrominGonane–±–––100???0?
NorethisteroneEstrane++–––67–751500–10–3160[66]
Norethisterone acetateaEstrane++–––205100??
Norethisterone enanthateaEstrane++–––???????
NoretynodrelaEstrane+±–––6020000
NorgestimateaGonane–+–––15001000
ProgesteronePregnane––±++500010100036
PromegestoneaNorpregnane–––+–1000055300
Segesterone acetateNorpregnane–––––1360038?0?
TiboloneaEstrane+++–––661????
Δ4-TibolonebEstrane–++–––903510210
TrimegestoneNorpregnane––±–±294–330109–1342–120??[66]
Footnotes: a = Prodrug. b = Metabolite (non-marketed). Class: Pregnane = Progesterone derivative. Norpregnane = 19-Norprogesterone derivative. Androstane = Testosterone derivative. Estrane = 19-Nortestosterone derivative. Gonane = 13β-Ethylgonane = 18-Methyl-19-nortestosterone derivative. Spirolactone = Spirolactone derivative. Magnitude: ++ = High. + = Moderate. ± = Low. – = None. Activity: ES = Estrogenic. AN = Androgenic. AA = Antiandrogenic. GC = Glucocorticoid. AM = Antimineralocorticoid. Binding: PR: Promegestone = 100%. AR: Metribolone = 100%. ER: Estradiol = 100%. GR: Dexamethasone = 100%. MR: Aldosterone = 100%. SHBG: DHT = 100%. CBG: Cortisol = 100%. Miscellaneous: Direct link to table. Sources:[70][1][71][72][73][74]
Pharmacodynamics of progestin metabolites
ProgestogenClassRBA (%)
PRARER
NorethisteroneEstrane67–75150
  5α-DihydronorethisteroneEstrane25270
LevonorgestrelGonane150–16234c, 450
  5α-DihydrolevonorgestrelGonane5038c0
NorgestimateaGonane1500
  NorelgestrominbGonane100?
  LevonorgestrelGonane150450
  Levonorgestrel 17β-acetateGonane135?0
DesogestrelaGonane100
  EtonogestrelbGonane150200
  3β-HydroxydesogestrelGonane1332
  5α-DihydroetonogestrelGonane9170
DienogestEstrane5100
  9α,10β-DihydrodienogestEstrane2613?
  3α,5α-TetrahydrodienogestEstrane1916?
TiboloneaEstrane661
  Δ4-TibolonebEstrane90351
  3α-HydroxytiboloneEstrane034
  3β-HydroxytiboloneEstrane043
Foototes: a = Prodrug. b = Main active metabolite. Binding: PR: Promegestone = 100%. AR: Metribolone (c = Mibolerone) = 100%. ER: Estradiol = 100%. Miscellaneous: Direct link to table. Sources:[1][70][66][75][76]
Oral potencies of progestogens
ProgestogenClassOID
(mg/day)		TFD
(mg/cycle)		TFD
(mg/day)		MDT
(mg/day)		ODP
(mg/day)		ECD
(mg/day)
AllylestrenolEstrane25150–250??–?
Chlormadinone acetatePregnane1.720–303.0–104.02.05–10
Cyproterone acetatePregnane1.020–301–34.02.01.0
DesogestrelGonane0.060.4–2.50.15?0.150.15
DienogestGonane1.06.0–6.3??2.0–3.02.0
DrospirenoneSpirolactone2.040–60??3.02.0
DydrogesteronePregnane>30140–20010–2020–10
Etynodiol diacetateEstrane2.010–15????
GestodeneGonane0.032.0–3.0??0.06–0.0750.20
LevonorgestrelGonane0.052.5–6.00.15–0.250.50.1–0.150.075
LynestrenolEstrane2.050–1505.010??
MedrogestonePregnane1050–1001015–10
Medroxyprogesterone acetatePregnane1040–1203–1020–30?5.0
Megestrol acetatePregnane?40–50???5.0
Nomegestrol acetatePregnane1.25–5.01005.0?2.53.75–5.0
NorethisteroneEstrane0.4100–150??0.50.7–1.0
Norethisterone acetateEstrane0.540–605.07.50.61.0
NoretynodrelEstrane4.0150??2.5–10?
NorgestimateGonane0.22.0–10??0.250.09
NorgestrelGonane0.112?0.5–2.0??
Progesterone (micronized)Pregnane3004200200–300?–200
PromegestonePregnane0.5100.5?–0.5
TiboloneEstrane2.5???–?
TrimegestonePregnane0.5?0.25–0.5??0.0625–0.5
Abbreviations: OID = Ovulation-inhibiting dosage (antigonadotropic effect; without an estrogen); TFD = Endometrial transformation dosage; ODP = Oral dosage in commercial contraceptive preparations; ECD = Estimated comparable dosage; MDT = Menstrual delay test (Greenblatt). Miscellaneous: Direct link to table. Sources:[70][6][49][72][77][78][79][80]
Parenteral potencies of progestogens
ProgestogenTypeClassTFD
(14 days)		MDT
(week)		OID
(month)		POIC-D
(2–3 months)		CIC-D
(month)		Duration
Algestone acetophenideSyntheticPregnaneNDNDNDNA75–150 mgND
Gestonorone caproateSyntheticNorpregnaneNDNDNDNANAND
Hydroxyprogesterone caproateSyntheticPregnane250–500 mg25 mg250–500 mgNA250–500 mg250 mg ≈ 10 days
Medroxyprogesterone acetateSyntheticPregnane50–100 mgNDND150 mg25 mg50 mg ≈ 14 days
Megestrol acetateSyntheticPregnaneNDNDNDNA25 mgND
Norethisterone enanthateSyntheticEstraneNDNDND200 mg50 mgND
Progesterone (oil soln.)BioidenticalPregnane200 mgNDNDNANA25 mg ≈ 2–3 days
Progesterone (cryst. susp.)BioidenticalPregnane50–100 mgNDNDNANA50 mg ≈ 14 days
Notes: All by intramuscular injection. Abbreviations: TFD = Endometrial transformation dose. MDT = Menstrual delay test dose (Greenblatt). OID = Ovulation-inhibiting dose (antigonadotropic effect; without an estrogen). POIC-D = Progestogen-only injectable contraceptive dose(s). CIC-D = Combined injectable contraceptive dose(s). Miscellaneous: Direct link to table. Sources:[81][82][83][84][85]

Antigonadotropic effects

Progestogens, similarly to the androgens and estrogens through their own respective receptors, inhibit the secretion of the gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) via activation of the PR in the pituitary gland. This effect is a form of negative feedback on the hypothalamic–pituitary–gonadal axis (HPG axis) and takes advantage of the mechanism that the body uses to prevent sex hormone levels from becoming too high.[86][42][87] Accordingly, progestogens, both endogenous and exogenous (i.e., progestins), have antigonadotropic effects,[44] and progestins in sufficiently high amounts can markedly suppress the body's normal production of progestogens, androgens, and estrogens as well as inhibit fertility (ovulation in women and spermatogenesis in men).[87]

Progestins have been found to maximally suppress circulating testosterone levels in men by up to 70 to 80% at sufficiently high dosages.[88][89] This is notably less than that achieved by GnRH analogues, which can effectively abolish gonadal production of testosterone and suppress circulating testosterone levels by as much as 95%.[90] It is also less than that achieved by high-dose estrogen therapy, which can suppress testosterone levels into the castrate range similarly to GnRH analogues.[91]

The retroprogesterone derivatives dydrogesterone and trengestone are atypical progestogens and unlike all other clinically used progestogens do not have antigonadotropic effects nor inhibit ovulation even at very high dosages.[1][92] In fact, trengestone may have progonadotropic effects, and is actually able to induce ovulation, with about a 50% success rate on average.[92] These progestins also show other atypical properties relative to other progestogens, such as a lack of a hyperthermic effect.[1][92]

Androgenic activity

Some progestins have androgenic activity and can produce androgenic side effects such as increased sebum production (oilier skin), acne, and hirsutism (excessive facial/body hair growth), as well as changes in liver protein production.[93][94][95] Only certain progestins are androgenic however, these being the testosterone derivatives and, to a lesser extent, the 17α-hydroxyprogesterone derivatives medroxyprogesterone acetate and megestrol acetate.[96][94][70] No other progestins have such activity (though some, conversely, possess antiandrogenic activity).[94][70] Moreover, the androgenic activity of progestins within the testosterone derivatives also varies, and while some may have high or moderate androgenic activity, others have only low or no such activity.[21][97]

The androgenic activity of androgenic progestins is mediated by two mechanisms: 1) direct binding to and activation of the androgen receptor; and 2) displacement of testosterone from sex hormone-binding globulin (SHBG), thereby increasing free (and thus bioactive) testosterone levels.[98] The androgenic activity of many androgenic progestins is offset by combination with ethinylestradiol, which robustly increases SHBG levels, and most oral contraceptives in fact markedly reduce free testosterone levels and can treat or improve acne and hirsutism.[98] An exception is progestin-only contraceptives, which do not also contain an estrogen.[98]

The androgenic activity of testosterone-derivative progestins and other progestins that have androgenic activity can be roughly ranked as follows:

It should be noted however that the clinical androgenic and anabolic activity of the androgenic progestins listed above is still far lower than that of conventional androgens and anabolic steroids like testosterone and nandrolone esters. As such, they are only generally associated with such effects in women and often only at high dosages. In men, due to their concomitant progestogenic activity and by extension antigonadotropic effects, these progestins can have potent functional antiandrogenic effects via suppression of testosterone production and levels.

On the other hand, some progestins have antiandrogenic activity in addition to their progestogenic activity.[116] These progestins, with varying degrees of potency as antiandrogens, include chlormadinone acetate, cyproterone acetate, dienogest, drospirenone, medrogestone, megestrol acetate, nomegestrol acetate, osaterone acetate (veterinary), and oxendolone.[116][115][117][118] The relative antiandrogenic activity in animals of some of these progestins has been ranked as follows: cyproterone acetate (100%) > nomegestrol acetate (90%) > dienogest (30–40%) ≥ chlormadinone acetate (30%) = drospirenone (30%).[1][119] Antiandrogenic activity in certain progestins may help to improve symptoms of acne, seborrhea, hirsutism, and other androgen-dependent conditions in women.[1][116]

Estrogenic activity

A few progestins have weak estrogenic activity.[1] These include the 19-nortestosterone derivatives norethisterone, noretynodrel, and tibolone, as well as the norethisterone prodrugs[120] norethisterone acetate, norethisterone enanthate, lynestrenol, and etynodiol diacetate.[1] The estrogenic activity of norethisterone and its prodrugs are due to metabolism into ethinylestradiol.[1] High dosages of norethisterone and noretynodrel have been associated with estrogenic side effects such as breast enlargement in women and gynecomastia in men, but also with alleviation of menopausal symptoms in postmenopausal women.[121] In contrast, non-estrogenic progestins were not found to be associated with such effects.[121]

Glucocorticoid activity

Some progestins, mainly certain 17α-hydroxyprogesterone derivatives, have weak glucocorticoid activity.[122] This can result, at sufficiently high dosages, in side effects such as symptoms of Cushing's syndrome, steroid diabetes, adrenal suppression and insufficiency, and neuropsychiatric symptoms like depression, anxiety, irritability, and cognitive impairment.[122][123][124] Progestins with the potential for clinically relevant glucocorticoid effects include the 17α-hydroxyprogesterone derivatives chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, megestrol acetate, promegestone, and segesterone acetate and the testosterone derivatives desogestrel, etonogestrel, and gestodene.[1][123][125][126] Conversely, hydroxyprogesterone caproate possesses no such activity, while progesterone itself has very weak glucocorticoid activity.[127][1]

Glucocorticoid activity of selected steroids in vitro
SteroidTypeTR (↑)aGR (%)b
DexamethasoneCorticosteroid++100
EthinylestradiolEstrogen–0
EtonogestrelProgestin+14
GestodeneProgestin+27
LevonorgestrelProgestin–1
Medroxyprogesterone acetateProgestin+29
NorethisteroneProgestin–0
NorgestimateProgestin–1
ProgesteroneProgestogen+10
Footnotes: a = Thrombin receptor (TR) upregulation (↑) in vascular smooth muscle cells (VSMCs). b = RBA (%) for the glucocorticoid receptor (GR). Strength: – = No effect. + = Pronounced effect. ++ = Strong effect. Miscellaenous: Direct link to table. Source:[1]

Antimineralocorticoid activity

Certain progestins, including drospirenone and gestodene and to a lesser extent dydrogesterone and trimegestone, have varying degrees of antimineralocorticoid activity.[1][58] Progesterone itself has potent antimineralocorticoid activity.[1] No clinically used progestins are known to have mineralocorticoid activity.[1] Progestins with potent antimineralocorticoid activity like drospirenone may have properties more similar to those of natural progesterone, such as counteraction of cyclical estrogen-induced sodium and fluid retention, edema, and associated weight gain; lowered blood pressure; and possibly improved cardiovascular health.[128][129][130][131]

Neurosteroid activity

Progesterone has neurosteroid activity via metabolism into allopregnanolone and pregnanolone, potent positive allosteric modulators of the GABAA receptor.[1] As a result, it has associated effects such as sedation, somnolence, and cognitive impairment.[1] No progestin is known to have similar such neurosteroid activity or effects.[1] However, promegestone has been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor similarly to progesterone.[132]

Pharmacokinetics

Pharmacokinetics of progestogens
ProgestogenClassDoseBAHalf-lifeRefs
AllylestrenolEstraneNA?Prodrug
Chlormadinone acetatePregnane2 mg~100%80 hours
Cyproterone acetatePregnane2 mg~100%54–79 hours
DesogestrelGonane0.15 mg63%Prodrug
DienogestGonane4 mg96%11–12 hours
DrospirenoneSpirolactone3 mg66%31–33 hours
DydrogesteronePregnane10 mg28%14–17 hours
Etynodiol diacetateEstraneNA?Prodrug
GestodeneGonane0.075 mg88–99%12–14 hours
Hydroxyprogesterone caproatePregnaneND?8 daysa[133]
LevonorgestrelGonane0.15–0.25 mg90%10–13 hours
LynestrenolEstraneNA?Prodrug
MedrogestonePregnane5 mg~100%35 hours
Medroxyprogesterone acetatePregnane10 mg~100%24 hours
Megestrol acetatePregnane160 mg~100%22 hours
Nomegestrol acetatePregnane2.5 mg60%50 hours[134][135]
NorethisteroneEstrane1 mg64%8 hours
Norethisterone acetateEstraneNA?Prodrug
NoretynodrelEstraneNA?Prodrug
NorgestimateGonaneNA?Prodrug
Progesterone (micronized)Pregnane100–200 mg<2.4%5 hours[136][137]
PromegestonePregnaneNA?Prodrug
TiboloneEstraneNA?Prodrug
TrimegestonePregnane0.5 mg~100%15 hours
Footnotes: a = By intramuscular injection. Miscellaneous: Direct link to table. Sources:[70][6][138][49][72]

Chemistry

All currently available progestins are steroids.[1] They include the pregnanes (e.g., dydrogesterone, medroxyprogesterone acetate) and norpregnanes (e.g., nomegestrol acetate), which are derivatives of progesterone, and the androstanes (e.g., danazol, ethisterone) and estranes (e.g., norethisterone, levonorgestrel), which are testosterone derivatives.[1] These groups can be further divided into various subgroups.[1]

History

The recognition of progesterone's ability to suppress ovulation during pregnancy spawned a search for a similar hormone that could bypass the problems associated with administering progesterone (e.g. low bioavailability when administered orally and local irritation and pain when continually administered parenterally) and, at the same time, serve the purpose of controlling ovulation. The many synthetic hormones that resulted are known as progestins.

The first orally active progestin, ethisterone (pregneninolone, 17α-ethynyltestosterone), the 17α-ethynyl analog of testosterone, was synthesized in 1938 from dehydroandrosterone by ethynylation, either before or after oxidation of the 3-OH group, followed by rearrangement of the 5,6 double bond to the 4,5 position. The synthesis was designed by chemists Hans Herloff Inhoffen, Willy Logemann, Walter Hohlweg and Arthur Serini at Schering AG in Berlin and was marketed in Germany in 1939 as Proluton C and by Schering in the U.S. in 1945 as Pranone.[139][140][141][142][143]

A more potent orally active progestin, norethisterone (norethindrone, 19-nor-17α-ethynyltestosterone), the 19-nor analog of ethisterone, synthesized in 1951 by Carl Djerassi, Luis Miramontes, and George Rosenkranz at Syntex in Mexico City, was marketed by Parke-Davis in the U.S. in 1957 as Norlutin, and was used as the progestin in some of the first oral contraceptives (Ortho-Novum, Norinyl, etc.) in the early 1960s.[140][140][141][142][143][144]

Noretynodrel, an isomer of norethisterone, was synthesized in 1952 by Frank B. Colton at Searle in Skokie, Illinois and used as the progestin in Enovid, marketed in the U.S. in 1957 and approved as the first oral contraceptive in 1960.[140][141][142][143][145]

Introduction of first-generation oral contraceptives
ProgestinEstrogenBrand nameManufacturerU.S. ApprovalU.K. Approval
NoretynodrelMestranolEnovidSearle19601963
NorethisteroneMestranolOrtho-Novum, NorinylSyntex/Ortho19631966
NorethisteroneEthinylestradiolNorlestrinSyntex/Parke-Davis19641962
LynestrenolMestranolLyndiolOrganonN/A1963
Megestrol acetateEthinylestradiolVolidan, NuvaconBritish Drug HousesN/A1963
Norethisterone acetateEthinylestradiolNorlestrinParke-Davis1964N/D
Quingestanol acetateEthinylestradiolRiglovisVisterN/AN/A
Quingestanol acetateQuinestrolUnovisWarner ChilcottN/AN/A
Medroxyprogesterone acetateEthinylestradiolProvestUpjohn1964N/A
Chlormadinone acetateMestranolC-QuensMerck19651965
DimethisteroneEthinylestradiolOraconBritish Drug Houses1965N/A
Etynodiol diacetateMestranolOvulenSearle19661965
Etynodiol diacetateEthinylestradiolDemulenSearle19701968
NorgestrienoneEthinylestradiolPlanor, MiniplanorRoussel UclafN/AN/A
NorgestrelEthinylestradiolOvralWyeth19681972
Anagestone acetateMestranolNeo-NovumOrthoN/AN/A
LynestrenolEthinylestradiolLyndiolOrganonN/A1969
Sources: Main:[146][147][148][149] Supplementary:[150][151][152] Miscellaneous: Direct link to table.

Society and culture

Generations

Progestins used in birth control are sometimes grouped, somewhat arbitrarily and fairly inconsistently, into generations. One definition of these generations is as follows:[14]

Alternatively, estranes such as noretynodrel and norethisterone are classified as first-generation while gonanes such as norgestrel and levonorgestrel are classified as second-generation, with less androgenic gonanes such as desogestrel, norgestimate, and gestodene classified as third-generation and newer progestins like drospirenone classified as fourth-generation.[15] Yet another classification system considers there to be only first- and second-generation progestins.

Availability

Progestins are available widely throughout the world in many different forms. They are present in all birth control pills.

Research

A variety of progestins have been studied for use as potential male hormonal contraceptives in combination with androgens in men.[24] These include the pregnanes medroxyprogesterone acetate, megestrol acetate, and cyproterone acetate, the norpregnane segesterone acetate, and the estranes norethisterone acetate, norethisterone enanthate, levonorgestrel, levonorgestrel butanoate, desogestrel, and etonogestrel.[24][153][154][155] The androgens that have been used in combination with these progestins include testosterone, testosterone esters, androstanolone (dihydrotestosterone), and nandrolone esters.[24] Dual androgens and progestins such as trestolone and dimethandrolone undecanoate have also been developed and studied as male contraceptives.[156][157]

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  2. 1 2 3 4 5 6 Wiegratz I, Kuhl H (2004). "Progestogen therapies: differences in clinical effects?". Trends Endocrinol. Metab. 15 (6): 277–85. doi:10.1016/j.tem.2004.06.006. PMID 15358281.
  3. 1 2 Thibaut F, De La Barra F, Gordon H, Cosyns P, Bradford JM (2010). "The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of paraphilias". World J. Biol. Psychiatry. 11 (4): 604–55. doi:10.3109/15622971003671628. PMID 20459370.
  4. 1 2 Glasier, Anna (March 20, 2015). "Chapter 134. Contraception". In Jameson, J. Larry; De Groot, Leslie J.; de Krester, David; Giudice, Linda C.; Grossman, Ashley; Melmed, Shlomo; Potts, John T., Jr.; Weir, Gordon C. Endocrinology: Adult and Pediatric (7th ed.). Philadelphia: Saunders Elsevier. p. 2306. ISBN 978-0-323-18907-1.
  5. 1 2 Pattman, Richard; Sankar, K. Nathan; Elewad, Babiker; Handy, Pauline; Price, David Ashley, eds. (November 19, 2010). "Chapter 33. Contraception including contraception in HIV infection and infection reduction". Oxford Handbook of Genitourinary Medicine, HIV, and Sexual Health (2nd ed.). Oxford: Oxford University Press. p. 360. ISBN 978-0-19-957166-6. Ovulation may be suppressed in 15–40% of cycles by POPs containg levonorgestrel, norethisterone, or etynodiol diacetate, but in 97–99% by those containing desogestrel.
  6. 1 2 3 4 Kuhl H (2011). "Pharmacology of Progestogens" (PDF). J Reproduktionsmed Endokrinol. 8 (1): 157–177.
  7. 1 2 Christian Lauritzen; John W. W. Studd (22 June 2005). Current Management of the Menopause. CRC Press. p. 45. ISBN 978-0-203-48612-2. Ethisterone, the first orally effective progestagen, was synthesized by Inhoffen and Hohlweg in 1938. Norethisterone, a progestogen still used worldwide, was synthesized by Djerassi in 1951. But this progestogen was not used immediately and in 1953 Colton discovered norethynodrel, used by Pincus in the first oral contraceptive. Numerous other progestogens were subsequently synthesized, e.g., lynestrenol and ethynodiol diacetate, which were, in fact, prhormones converted in vivo to norethisterone. All these progestogens were also able to induce androgenic effects when high doses were used. More potent progestogens were synthesized in the 1960s, e.g. norgestrel, norgestrienone. These progestogens were also more androgenic.
  8. ↑ Klaus Roth (2014). Chemische Leckerbissen. John Wiley & Sons. p. 69. ISBN 978-3-527-33739-2. Im Prinzip hatten Hohlweg und Inhoffen die Lösung schon 1938 in der Hand, denn ihr Ethinyltestosteron (11) war eine oral wirksame gestagene Verbindung und Schering hatte daraus bereits 1939 ein Medikament (Proluton C®) entwickelt.
  9. 1 2 http://www.micromedexsolutions.com
  10. 1 2 Sweetman, Sean C., ed. (2009). "Sex hormones and their modulators". Martindale: The Complete Drug Reference (36th ed.). London: Pharmaceutical Press. ISBN 978-0-85369-840-1.
  11. 1 2 https://www.drugs.com/drug-class/progestins.html
  12. 1 2 Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. ISBN 978-3-88763-075-1.
  13. ↑ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. ISBN 978-1-4757-2085-3.
  14. 1 2 John David Gordon; Jan Rydfors; Maurice Druzin; Yasser El-Sayed; Yona Tadir (2007). Obstetrics, Gynecology & Infertility: Handbook for Clinicians. Scrub Hill Press, Inc. pp. 229–. ISBN 978-0-9645467-7-6.
  15. 1 2 Ronald S. Gibbs (2008). Danforth's Obstetrics and Gynecology. Lippincott Williams & Wilkins. pp. 568–. ISBN 978-0-7817-6937-2.
  16. ↑ J. Larry Jameson; Leslie J. De Groot (25 February 2015). Endocrinology: Adult and Pediatric E-Book. Elsevier Health Sciences. pp. 2304–. ISBN 978-0-323-32195-2.
  17. 1 2 Michelle A. Clark; Richard A. Harvey; Richard Finkel; Jose A. Rey; Karen Whalen (15 December 2011). Pharmacology. Lippincott Williams & Wilkins. p. 322. ISBN 978-1-4511-1314-3.
  18. 1 2 Bhattacharya (1 January 2003). Pharmacology, 2/e. Elsevier India. p. 378. ISBN 978-81-8147-009-6.
  19. ↑ Rick D. Kellerman; Edward T. Bope (10 November 2017). Conn's Current Therapy 2018 E-Book. Elsevier Health Sciences. pp. 1124–. ISBN 978-0-323-52961-7.
  20. ↑ Helen Varney; Jan M. Kriebs; Carolyn L. Gegor (2004). Varney's Midwifery. Jones & Bartlett Learning. pp. 513–. ISBN 978-0-7637-1856-5.
  21. 1 2 3 4 David E. Golan (2008). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 520–521. ISBN 978-0-7817-8355-2.
  22. ↑ Pamela S. Miles; William F. Rayburn; J.Christopher Carey (6 December 2012). Obstetrics and Gynecology. Springer Science & Business Media. pp. 109–. ISBN 978-1-4684-0220-9.
  23. 1 2 Erkkola R, Landgren BM (March 2005). "Role of progestins in contraception". Acta Obstet Gynecol Scand. 84 (3): 207–16. doi:10.1111/j.0001-6349.2005.00759.x. PMID 15715527.
  24. 1 2 3 4 Nieschlag E (2010). "Clinical trials in male hormonal contraception" (PDF). Contraception. 82 (5): 457–70. doi:10.1016/j.contraception.2010.03.020. PMID 20933120.
  25. ↑ Guise TA, Oefelein MG, Eastham JA, Cookson MS, Higano CS, Smith MR (2007). "Estrogenic side effects of androgen deprivation therapy". Rev Urol. 9 (4): 163–80. PMC 2213888. PMID 18231613.
  26. ↑ Frisk J (2010). "Managing hot flushes in men after prostate cancer--a systematic review". Maturitas. 65 (1): 15–22. doi:10.1016/j.maturitas.2009.10.017. PMID 19962840.
  27. ↑ Koike H, Morikawa Y, Matsui H, Shibata Y, Ito K, Suzuki K (2013). "Chlormadinone acetate is effective for hot flush during androgen deprivation therapy". Prostate Int. 1 (3): 113–6. doi:10.12954/PI.12010. PMC 3814123. PMID 24223412.
  28. ↑ Hickey M, Fraser IS (August 2000). "A functional model for progestogen-induced breakthrough bleeding". Hum. Reprod. 15 Suppl 3: 1–6. doi:10.1093/humrep/15.suppl_3.1. PMID 11041215.
  29. 1 2 3 Schindler AE (February 2011). "Dydrogesterone and other progestins in benign breast disease: an overview". Arch. Gynecol. Obstet. 283 (2): 369–71. doi:10.1007/s00404-010-1456-7. PMID 20383772.
  30. 1 2 3 Winkler UH, Schindler AE, Brinkmann US, Ebert C, Oberhoff C (December 2001). "Cyclic progestin therapy for the management of mastopathy and mastodynia". Gynecol. Endocrinol. 15 Suppl 6: 37–43. PMID 12227885.
  31. 1 2 Ruan X, Mueck AO (2014). "Systemic progesterone therapy--oral, vaginal, injections and even transdermal?". Maturitas. 79 (3): 248–55. doi:10.1016/j.maturitas.2014.07.009. PMID 25113944.
  32. ↑ Bińkowska, Małgorzata; Woroń, Jarosław (2015). "Progestogens in menopausal hormone therapy". Menopausal Review. 2: 134–143. doi:10.5114/pm.2015.52154. ISSN 1643-8876.
  33. ↑ Kistner RW (1959). "Histological effects of progestins on hyperplasia and carcinoma in situ of the endometrium". Cancer. 12: 1106–22. doi:10.1002/1097-0142(195911/12)12:6<1106::aid-cncr2820120607>3.0.co;2-m. PMID 14409476.
  34. ↑ Regulatory Mechanisms in Transcriptional Signaling. Academic Press. 25 July 2009. pp. 62–. ISBN 978-0-08-091198-4.
  35. ↑ Loren K. Mell, MD (20 December 2011). Gynecologic Cancer. Demos Medical Publishing. pp. 393–. ISBN 978-1-61705-095-4.
  36. ↑ Robert G. McKinnell (13 March 1998). The Biological Basis of Cancer. Cambridge University Press. pp. 262–. ISBN 978-0-521-59695-4.
  37. ↑ Jacqueline Burchum; Laura Rosenthal (2 December 2014). Lehne's Pharmacology for Nursing Care - E-Book. Elsevier Health Sciences. pp. 740–. ISBN 978-0-323-34026-7.
  38. ↑ H. John Smith; Hywel Williams (10 October 2005). Smith and Williams' Introduction to the Principles of Drug Design and Action, Fourth Edition. CRC Press. pp. 493–. ISBN 978-0-203-30415-0.
  39. 1 2 3 4 5 6 David J. Winchester (2006). Breast Cancer. PMPH-USA. pp. 333–. ISBN 978-1-55009-272-1.
  40. 1 2 Gadducci A, Genazzani AR (December 1999). "Endocrine therapy for gynecological cancer". Gynecol. Endocrinol. 13 (6): 441–56. doi:10.3109/09513599909167590. PMID 10685337.
  41. 1 2 Loose, Davis S.; Stancel, George M. (2006). "Estrogens and Progestins". In Brunton, Laurence L.; Lazo, John S.; Parker, Keith L. Goodman & Gilman's The Pharmacological Basis of Therapeutics (11th ed.). New York: McGraw-Hill. pp. 1541–71. ISBN 0-07-142280-3.
  42. 1 2 Chassard D, Schatz B (2005). "[The antigonadrotropic activity of chlormadinone acetate in reproductive women]". Gynécologie, Obstétrique & Fertilité (in French). 33 (1–2): 29–34. doi:10.1016/j.gyobfe.2004.12.002. PMID 15752663.
  43. ↑ Andrea R. Genazzani (15 January 1993). Frontiers in Gynecologic and Obstetric Investigation. Taylor & Francis. p. 320. ISBN 978-1-85070-486-7. Retrieved 29 May 2012.
  44. 1 2 Neumann F (1978). "The physiological action of progesterone and the pharmacological effects of progestogens--a short review". Postgraduate Medical Journal. 54 Suppl 2: 11–24. PMID 368741.
  45. ↑ Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS (January 2006). "Secondary hormonal therapy for advanced prostate cancer". J. Urol. 175 (1): 27–34. doi:10.1016/S0022-5347(05)00034-0. PMID 16406864.
  46. 1 2 Fourcade RO, Chatelain C (July 1998). "Androgen deprivation for prostatic carcinoma: a rationale for choosing components". Int. J. Urol. 5 (4): 303–11. doi:10.1111/j.1442-2042.1998.tb00356.x. PMID 9712436.
  47. ↑ Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D (March 2001). "High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials". Ann. Oncol. 12 (3): 289–300. doi:10.1023/a:1011156811739. PMID 11332139.
  48. ↑ Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D (June 2003). "Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal". J Chemother. 15 (3): 220–5. doi:10.1179/joc.2003.15.3.220. PMID 12868546.
  49. 1 2 3 4 5 Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. doi:10.1016/0378-5122(90)90004-P. PMID 2215269.
  50. 1 2 Africander D, Verhoog N, Hapgood JP (June 2011). "Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception". Steroids. 76 (7): 636–52. doi:10.1016/j.steroids.2011.03.001. PMID 21414337.
  51. ↑ Worly, Brett L.; Gur, Tamar L.; Schaffir, Jonathan (2018). "The relationship between progestin hormonal contraception and depression: a systematic review". Contraception. doi:10.1016/j.contraception.2018.01.010. ISSN 0010-7824.
  52. ↑ Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø (November 2016). "Association of Hormonal Contraception With Depression". JAMA Psychiatry. 73 (11): 1154–1162. doi:10.1001/jamapsychiatry.2016.2387. PMID 27680324.
  53. ↑ Jacobsen BM, Horwitz KB (2012). "Progesterone receptors, their isoforms and progesterone regulated transcription". Mol. Cell. Endocrinol. 357 (1–2): 18–29. doi:10.1016/j.mce.2011.09.016. PMC 3272316. PMID 21952082.
  54. ↑ Scarpin KM, Graham JD, Mote PA, Clarke CL (2009). "Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression". Nucl Recept Signal. 7: e009. doi:10.1621/nrs.07009. PMC 2807635. PMID 20087430.
  55. ↑ Thomas P, Pang Y (2012). "Membrane progesterone receptors: evidence for neuroprotective, neurosteroid signaling and neuroendocrine functions in neuronal cells". Neuroendocrinology. 96 (2): 162–71. doi:10.1159/000339822. PMC 3489003. PMID 22687885.
  56. ↑ Petersen SL, Intlekofer KA, Moura-Conlon PJ, Brewer DN, Del Pino Sans J, Lopez JA (2013). "Novel progesterone receptors: neural localization and possible functions". Frontiers in Neuroscience. 7: 164. doi:10.3389/fnins.2013.00164. PMC 3776953. PMID 24065878.
  57. ↑ Gompel A, Plu-Bureau G (August 2018). "Progesterone, progestins and the breast in menopause treatment". Climacteric. 21 (4): 326–332. doi:10.1080/13697137.2018.1476483. PMID 29852797.
  58. 1 2 Regidor PA, Schindler AE (2017). "Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone". Oncotarget. 8 (47): 83334–83342. doi:10.18632/oncotarget.19833. PMC 5669973. PMID 29137347.
  59. ↑ Bergink, E.W.; Loonen, P.B.A.; Kloosterboer, H.J. (1985). "Receptor binding of allylestrenol, a progestagen of the 19-nortestosterone series without androgenic properties". Journal of Steroid Biochemistry. 23 (2): 165–168. doi:10.1016/0022-4731(85)90232-8. ISSN 0022-4731. PMID 3928974.
  60. ↑ Madjerek, Z.; de Visser, J.; van der Vies, J.; Overbeek, G. A. (1960). "Allylestrenol, a Pregnancy Maintaining Oral Gestagen". European Journal of Endocrinology. XXXV (I): 8–19. doi:10.1530/acta.0.XXXV0008. ISSN 0804-4643.
  61. ↑ Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (January 1980). "Steroid flexibility and receptor specificity". J. Steroid Biochem. 13 (1): 45–59. doi:10.1016/0022-4731(80)90112-0. PMID 7382482.
  62. ↑ Raynaud JP, Bouton MM, Moguilewsky M, Ojasoo T, Philibert D, Beck G, Labrie F, Mornon JP (January 1980). "Steroid hormone receptors and pharmacology". J. Steroid Biochem. 12: 143–57. PMID 7421203.
  63. 1 2 Ojasoo T, Raynaud JP, Doé JC (January 1994). "Affiliations among steroid receptors as revealed by multivariate analysis of steroid binding data". J. Steroid Biochem. Mol. Biol. 48 (1): 31–46. doi:10.1016/0960-0760(94)90248-8. PMID 8136304.
  64. 1 2 Ojasoo T, Raynaud JP (November 1978). "Unique steroid congeners for receptor studies". Cancer Res. 38 (11 Pt 2): 4186–98. PMID 359134.
  65. ↑ Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ (November 2000). "Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives". J. Steroid Biochem. Mol. Biol. 74 (4): 213–22. doi:10.1016/S0960-0760(00)00125-4. PMID 11162927.
  66. 1 2 3 4 5 6 Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M (October 1999). "The pharmacological profile of a novel norpregnance progestin (trimegestone)". Gynecol. Endocrinol. 13 (5): 316–26. doi:10.3109/09513599909167574. PMID 10599548.
  67. ↑ Geller, Jack (1965). "Treatment of Benign Prostatic Hypertrophy With Hydroxyprogesterone Caproate". JAMA. 193 (2): 121. doi:10.1001/jama.1965.03090020035009. ISSN 0098-7484. PMID 14304354.
  68. ↑ Meis PJ (2005). "17 hydroxyprogesterone for the prevention of preterm delivery". Obstet Gynecol. 105 (5 Pt 1): 1128–35. doi:10.1097/01.AOG.0000160432.95395.8f. PMID 15863556.
  69. ↑ Ralph I. Dorfman (5 December 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 398–. ISBN 978-1-4832-7299-3. Intramuscular administration of 17α-hydroxyprogesterone caproate produced signs and symptoms of adrenal insufficiency in Addisonians maintained on cortisol and 9α-fluorocortisol (Melby, 1961) and thereby showed properties similar to progesterone and 17α-hydroxyprogesterone. However, further tests will be required to eludicate its pharmacodynamics properties. Contrastingly, there was no evidence for salt dissipation with the test of a smaller dose of the steroid to normal subjects (Landau et al., 1958).
  70. 1 2 3 4 5 6 Schindler, Adolf E; Campagnoli, Carlo; Druckmann, René; Huber, Johannes; Pasqualini, Jorge R; Schweppe, Karl W; Thijssen, Jos H.H (2003). "Classification and pharmacology of progestins". Maturitas. 46: 7–16. doi:10.1016/j.maturitas.2003.09.014. ISSN 0378-5122. PMID 14670641.
  71. ↑ Schindler, Adolf E. (2015). "Pharmacology of Progestogens". Progestogens in Obstetrics and Gynecology: 33–40. doi:10.1007/978-3-319-14385-9_2.
  72. 1 2 3 Kuhl H (1990). "Pharmacokinetics of oestrogens and progestogens". Maturitas. 12 (3): 171–97. doi:10.1016/0378-5122(90)90003-o. PMID 2170822.
  73. ↑ Freimut A. Leidenberger; Thomas Strowitzki; Olaf Ortmann (29 August 2009). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 225, 227. ISBN 978-3-540-89760-6.
  74. ↑ J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 95–. ISBN 978-94-009-8195-9.
  75. ↑ Cabeza M, Vilchis F, Lemus AE, Díaz de León L, Pérez-Palacios G (September 1995). "Molecular interactions of levonorgestrel and its 5 alpha-reduced derivative with androgen receptors in hamster flanking organs". Steroids. 60 (9): 630–5. doi:10.1016/0039-128X(95)00075-2. PMID 8545853.
  76. ↑ Santillán R, Pérez-Palacios G, Reyes M, Damián-Matsumura P, García GA, Grillasca I, Lemus AE (September 2001). "Assessment of the oestrogenic activity of the contraceptive progestin levonorgestrel and its non-phenolic metabolites". Eur. J. Pharmacol. 427 (2): 167–74. doi:10.1016/S0014-2999(01)01263-8. PMID 11557270.
  77. ↑ Karl Knörr; Henriette Knörr-Gärtner; Fritz K. Beller; Christian Lauritzen (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
  78. ↑ Karl Knörr; Fritz K. Beller; Christian Lauritzen (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0.
  79. ↑ Freimut A. Leidenberger; Thomas Strowitzki; Olaf Ortmann (29 August 2009). Klinische Endokrinologie für Frauenärzte. Springer-Verlag. pp. 225, 227. ISBN 978-3-540-89760-6.
  80. ↑ Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–57. doi:10.1016/j.contraception.2011.04.009. PMID 22078182.
  81. ↑ Karl Knörr; Fritz K. Beller; Christian Lauritzen (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0.
  82. ↑ Karl Knörr; Henriette Knörr-Gärtner; Fritz K. Beller; Christian Lauritzen (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
  83. ↑ Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception. 49 (4): 361–85. doi:10.1016/0010-7824(94)90033-7. PMID 8013220.
  84. ↑ Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
  85. ↑ Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control" (PDF). World J Pharm Pharm Sci. 3 (10): 364–392. ISSN 2278-4357.
  86. ↑ de Lignières B, Silberstein S (April 2000). "Pharmacodynamics of oestrogens and progestogens". Cephalalgia : an International Journal of Headache. 20 (3): 200–7. doi:10.1046/j.1468-2982.2000.00042.x. PMID 10997774.
  87. 1 2 Brady BM, Anderson RA, Kinniburgh D, Baird DT (April 2003). "Demonstration of progesterone receptor-mediated gonadotrophin suppression in the human male". Clinical Endocrinology. 58 (4): 506–12. doi:10.1046/j.1365-2265.2003.01751.x. PMID 12641635.
  88. ↑ Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (25 August 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. pp. 2938–. ISBN 978-1-4160-6911-9.
  89. ↑ Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF (1979). "Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men". Clinical Endocrinology. 11 (5): 497–504. doi:10.1111/j.1365-2265.1979.tb03102.x. PMID 519881.
  90. ↑ Urotext (1 January 2001). Urotext-Luts: Urology. Urotext. pp. 71–. ISBN 978-1-903737-03-3.
  91. ↑ Jacobi GH, Altwein JE, Kurth KH, Basting R, Hohenfellner R (1980). "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial". Br J Urol. 52 (3): 208–15. doi:10.1111/j.1464-410x.1980.tb02961.x. PMID 7000222.
  92. 1 2 3 J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 329–. ISBN 978-94-009-8195-9.
  93. ↑ Bullock, Leslie P.; Bardin, C. W. (1977). "Androgenic, Synandrogenic, and Antiandrogenic Actions of Progestins". Annals of the New York Academy of Sciences. 286 (1 Biochemical A): 321–330. Bibcode:1977NYASA.286..321B. doi:10.1111/j.1749-6632.1977.tb29427.x. ISSN 0077-8923.
  94. 1 2 3 Darney, Philip D. (1995). "The androgenicity of progestins". The American Journal of Medicine. 98 (1): S104–S110. doi:10.1016/S0002-9343(99)80067-9. ISSN 0002-9343.
  95. ↑ Campagnoli, Carlo; Clavel-Chapelon, Françoise; Kaaks, Rudolf; Peris, Clementina; Berrino, Franco (2005). "Progestins and progesterone in hormone replacement therapy and the risk of breast cancer". The Journal of Steroid Biochemistry and Molecular Biology. 96 (2): 95–108. doi:10.1016/j.jsbmb.2005.02.014. ISSN 0960-0760. PMC 1974841. PMID 15908197.
  96. ↑ Kenneth Hugdahl; René Westerhausen (2010). The Two Halves of the Brain: Information Processing in the Cerebral Hemispheres. MIT Press. pp. 272–. ISBN 978-0-262-01413-7.
  97. 1 2 3 David A. Williams; William O. Foye; Thomas L. Lemke (January 2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 700–. ISBN 978-0-683-30737-5.
  98. 1 2 3 Ricardo Azziz (8 November 2007). Androgen Excess Disorders in Women. Springer Science & Business Media. pp. 124–. ISBN 978-1-59745-179-6.
  99. 1 2 P. J. Bentley (1980). Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 4–. ISBN 978-0-521-22673-8.
  100. ↑ Sengupta (1 January 2007). Gynaecology For Postgraduate And Practitioners. Elsevier India. pp. 137–. ISBN 978-81-312-0436-8.
  101. ↑ Ferin, J. (1962). "Artificial Induction of Hypoestrogenic Amenorrhea with Methylestrenolone, or with Lynestrenol". European Journal of Endocrinology. 39 (1): 47–67. doi:10.1530/acta.0.0390047. ISSN 0804-4643.
  102. ↑ Saunders, Francis J.; Drill, Victor A. (1956). "The Myotrophic and Androgenic Effects of 17-Ethyl-19-nortestosterone and Related Compounds". Endocrinology. 58 (5): 567–572. doi:10.1210/endo-58-5-567. ISSN 0013-7227. PMID 13317831.
  103. 1 2 3 Armen H. Tashjian; Ehrin J. Armstrong (21 July 2011). Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. Lippincott Williams & Wilkins. pp. 523–. ISBN 978-1-4511-1805-6.
  104. ↑ de Gooyer, Marcel E; Deckers, Godefrides H; Schoonen, Willem G.E.J; Verheul, Herman A.M; Kloosterboer, Helenius J (2003). "Receptor profiling and endocrine interactions of tibolone". Steroids. 68 (1): 21–30. doi:10.1016/S0039-128X(02)00112-5. ISSN 0039-128X. PMID 12475720. [Norethisterone] has similar and [norethynodrel] weaker androgenic effects compared to tibolone.
  105. ↑ Raynaud JP, Ojasoo T (1986). "The design and use of sex-steroid antagonists". J. Steroid Biochem. 25 (5B): 811–33. PMID 3543501. Similar androgenic potential is inherent to norethisterone and its prodrugs (norethisterone acetate, ethynodiol diacetate, lynestrenol, norethynodrel, quingestanol).
  106. 1 2 Chaudhuri (1 January 2007). Practice Of Fertility Control: A Comprehensive Manual (7Th Edition). Elsevier India. pp. 122–. ISBN 978-81-312-1150-2.
  107. ↑ Kuhl H (1996). "Comparative pharmacology of newer progestogens". Drugs. 51 (2): 188–215. doi:10.2165/00003495-199651020-00002. PMID 8808163.
  108. ↑ Stefan Offermanns; Walter Rosenthal (14 August 2008). Encyclopedia of Molecular Pharmacology. Springer Science & Business Media. pp. 391–. ISBN 978-3-540-38916-3.
  109. ↑ Lara Marks (2001). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 73–75, 77–78. ISBN 978-0-300-08943-1.
  110. ↑ KORN GW (1961). "The use of norethynodrel (enovid) in clinical practice". Can Med Assoc J. 84: 584–7. PMC 1939348. PMID 13753182. Pseudohermaphroditism should not be a problem in these patients as it appears that norethynodrel does not possess androgenic properties, but it is believed that Wilkins has now found one such case in a patient who has been on norethynodrel therapy.
  111. ↑ de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ (2003). "Receptor profiling and endocrine interactions of tibolone". Steroids. 68 (1): 21–30. doi:10.1016/s0039-128x(02)00112-5. PMID 12475720.
  112. ↑ Ruggieri, Pietro de; Matscher, Rodolfo; Lupo, Corrado; Spazzoli, Giacomo (1965). "Biological properties of 17α-vinyl-5(10)-estrene-17β-ol-3-one (norvinodrel) as a progestational and claudogenic compound". Steroids. 5 (1): 73–91. doi:10.1016/0039-128X(65)90133-9. ISSN 0039-128X.
  113. ↑ J. A. Simpson; E. S. C. Weiner (1997). Oxford English Dictionary Additions Series. Clarendon Press. pp. 36–. ISBN 978-0-19-860027-5.
  114. ↑ JUCKER (8 March 2013). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 166–. ISBN 978-3-0348-7053-5.
  115. 1 2 Annual Reports in Medicinal Chemistry. Academic Press. 8 September 1989. pp. 199–. ISBN 978-0-08-058368-6.
  116. 1 2 3 Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226.
  117. ↑ Schneider HP (2003). "Androgens and antiandrogens". Annals of the New York Academy of Sciences. 997: 292–306. Bibcode:2003NYASA.997..292S. doi:10.1196/annals.1290.033. PMID 14644837.
  118. ↑ Botella, J.; Paris, J.; Lahlou, B. (1987). "The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-nor progestagen, on the rat prostate". European Journal of Endocrinology. 115 (4): 544–550. doi:10.1530/acta.0.1150544. ISSN 0804-4643.
  119. ↑ Wiegratz I, Kuhl H (2006). "Metabolic and clinical effects of progestogens". Eur J Contracept Reprod Health Care. 11 (3): 153–61. doi:10.1080/13625180600772741. PMID 17056444.
  120. ↑ Hammerstein J (1990). "Prodrugs: advantage or disadvantage?". Am. J. Obstet. Gynecol. 163 (6 Pt 2): 2198–203. PMID 2256526.
  121. 1 2 Paulsen CA, Leach RB, Lanman J, Goldston N, Maddock WO, Heller CG (1962). "Inherent estrogenicity of norethindrone and norethynodrel: comparison with other synthetic progestins and progesterone". J. Clin. Endocrinol. Metab. 22: 1033–9. doi:10.1210/jcem-22-10-1033. PMID 13942007.
  122. 1 2 Neumann, F.; Duesterberg, B.; Laurent, H. (1988). "Development of Progestogens". Female Contraception: 129–140. doi:10.1007/978-3-642-73790-9_11.
  123. 1 2 Philip W. Harvey (28 March 1996). Adrenal in Toxicology: Target Organ and Modulator of Toxicity. CRC Press. pp. 284–. ISBN 978-0-7484-0330-1.
  124. ↑ Alfred Cuschieri; George Hanna (20 January 2015). Essential Surgical Practice: Higher Surgical Training in General Surgery, Fifth Edition. CRC Press. pp. 899–. ISBN 978-1-4441-3763-7.
  125. ↑ John A. Thomas (12 March 1997). Endocrine Toxicology, Second Edition. CRC Press. pp. 152–. ISBN 978-1-4398-1048-4.
  126. ↑ Nick Panay; Paula Briggs; Gab Kovacs (20 August 2015). Managing the Menopause. Cambridge University Press. pp. 126–. ISBN 978-1-107-45182-7.
  127. ↑ Meis, Paul J. (2005). "17 Hydroxyprogesterone for the Prevention of Preterm Delivery". Obstetrics & Gynecology. 105 (5, Part 1): 1128–1135. doi:10.1097/01.AOG.0000160432.95395.8f. ISSN 0029-7844. PMID 15863556.
  128. ↑ Oelkers W (2002). "Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone". Eur J Contracept Reprod Health Care. 7 Suppl 3: 19–26, discussion 42–3. PMID 12659403.
  129. ↑ Foidart JM, Faustmann T (2007). "Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen". Gynecol. Endocrinol. 23 (12): 692–9. doi:10.1080/09513590701582323. PMID 18075844.
  130. ↑ Genazzani AR, Mannella P, Simoncini T (2007). "Drospirenone and its antialdosterone properties". Climacteric. 10 Suppl 1: 11–8. doi:10.1080/13697130601114891. PMID 17364593.
  131. ↑ Palacios S, Foidart JM, Genazzani AR (2006). "Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism". Maturitas. 55 (4): 297–307. doi:10.1016/j.maturitas.2006.07.009. PMID 16949774.
  132. ↑ Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.
  133. ↑ April Hazard Vallerand; Cynthia A Sanoski (4 June 2014). Davis's Canadian Drug Guide for Nurses®. F.A. Davis. pp. 658–. ISBN 978-0-8036-4086-3.
  134. ↑ Lello, Stefano (2010). "Nomegestrol Acetate". Drugs. 70 (5): 541–559. doi:10.2165/11532130-000000000-00000. ISSN 0012-6667. PMID 20329803.
  135. ↑ Ruan, Xiangyan; Seeger, Harald; Mueck, Alfred O. (2012). "The pharmacology of nomegestrol acetate". Maturitas. 71 (4): 345–353. doi:10.1016/j.maturitas.2012.01.007. ISSN 0378-5122.
  136. ↑ Levine H, Watson N (March 2000). "Comparison of the pharmacokinetics of Crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3)". Fertil. Steril. 73 (3): 516–21. doi:10.1016/S0015-0282(99)00553-1. PMID 10689005.
  137. ↑ Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B (December 2015). "Pharmacokinetics of the first combination 17β-estradiol/progesterone capsule in clinical development for menopausal hormone therapy". Menopause. 22 (12): 1308–16. doi:10.1097/GME.0000000000000467. PMC 4666011. PMID 25944519.
  138. ↑ Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 761–. ISBN 978-1-4511-4847-3.
  139. ↑ Inhoffen HH, Logemann W, Hohlweg W, Serini A (May 4, 1938). "Untersuchungen in der Sexualhormon-Reihe (Investigations in the sex hormone series)". Ber Dtsch Chem Ges. 71 (5): 1024–32. doi:10.1002/cber.19380710520.
  140. 1 2 3 4 Maisel, Albert Q. (1965). The Hormone Quest. New York: Random House. OCLC 543168.
  141. 1 2 3 Petrow V (1970). "The contraceptive progestagens". Chem Rev. 70 (6): 713–26. doi:10.1021/cr60268a004. PMID 4098492.
  142. 1 2 3 Sneader, Walter (2005). "Hormone analogues". Drug discovery : a history. Hoboken, NJ: John Wiley & Sons. pp. 188–225. ISBN 0-471-89980-1.
  143. 1 2 3 Djerassi C (2006). "Chemical birth of the pill". Am J Obstet Gynecol. 194 (1): 290–8. doi:10.1016/j.ajog.2005.06.010. PMID 16389046.
  144. ↑ Djerassi C, Miramontes L, Rosenkranz G, Sondheimer F (1954). "Steroids. LIV. Synthesis of 19-Nor-17α-ethynyltestosterone and 19-Nor-17α-methyltestosterone" (PDF). J Am Chem Soc. 76 (16): 4089–91. doi:10.1021/ja01645a009.
  145. ↑ Colton FB (1992). "Steroids and "the pill": early steroid research at Searle". Steroids. 57 (12): 624–30. doi:10.1016/0039-128X(92)90015-2. PMID 1481226.
  146. ↑ Lara Marks (2001). Sexual Chemistry: A History of the Contraceptive Pill. Yale University Press. pp. 73–75, 77–78. ISBN 978-0-300-08943-1.
  147. ↑ Annetine Gelijns (1991). Innovation in Clinical Practice: The Dynamics of Medical Technology Development. National Academies. pp. 167–. NAP:13513.
  148. ↑ Robert W. Blum (22 October 2013). Adolescent Health Care: Clinical Issues. Elsevier Science. pp. 216–. ISBN 978-1-4832-7738-7.
  149. ↑ Andrea Tone; Elizabeth Siegel Watkins (8 January 2007). Medicating Modern America: Prescription Drugs in History. NYU Press. pp. 117–119. ISBN 978-0-8147-8301-6.
  150. ↑ John L. McGuire (2000). Pharmaceuticals, 4 Volume Set. Wiley. p. 1580,1599. ISBN 978-3-527-29874-7.
  151. ↑ Bhasker Rao (1 January 1998). Clinical Gynecology (4Th Edition). Orient Blackswan. pp. 163–. ISBN 978-81-250-1622-9.
  152. ↑ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 571–. ISBN 978-3-642-96158-8.
  153. ↑ C. Coutifaris; L. Mastroianni (15 August 1997). New Horizons in Reproductive Medicine. CRC Press. pp. 101–. ISBN 978-1-85070-793-6.
  154. ↑ Shio Kumar Singh (4 September 2015). Mammalian Endocrinology and Male Reproductive Biology. CRC Press. pp. 270–. ISBN 978-1-4987-2736-5.
  155. ↑ Frick, J. (1973). "Control of spermatogenesis in men by combined administration of progestin and androgen". Contraception. 8 (3): 191–206. doi:10.1016/0010-7824(73)90030-9. ISSN 0010-7824.
  156. ↑ Nieschlag E, Kumar N, Sitruk-Ware R (2013). "7α-methyl-19-nortestosterone (MENTR): the population council's contribution to research on male contraception and treatment of hypogonadism". Contraception. 87 (3): 288–95. doi:10.1016/j.contraception.2012.08.036. PMID 23063338.
  157. ↑ Attardi BJ, Hild SA, Reel JR (2006). "Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity". Endocrinology. 147 (6): 3016–26. doi:10.1210/en.2005-1524. PMID 16497801.

Further reading

  • Kuhl H (September 1990). "Pharmacokinetics of oestrogens and progestogens". Maturitas. 12 (3): 171–97. doi:10.1016/0378-5122(90)90003-o. PMID 2170822.
  • Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens". Maturitas. 12 (3): 199–214. PMID 2215269.
  • Stanczyk FZ (September 2002). "Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception" (PDF). Rev Endocr Metab Disord. 3 (3): 211–24. doi:10.1023/A:1020072325818. PMID 12215716.
  • Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. PMID 12600226.
  • Stanczyk FZ (November 2003). "All progestins are not created equal". Steroids. 68 (10–13): 879–90. PMID 14667980.
  • Nieschlag E, Zitzmann M, Kamischke A (November 2003). "Use of progestins in male contraception". Steroids. 68 (10–13): 965–72. PMID 14667989.
  • Wiegratz I, Kuhl H (August 2004). "Progestogen therapies: differences in clinical effects?". Trends Endocrinol. Metab. 15 (6): 277–85. doi:10.1016/j.tem.2004.06.006. PMID 15358281.
  • Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
  • Sitruk-Ware R (October 2005). "Pharmacology of different progestogens: the special case of drospirenone". Climacteric. 8 Suppl 3: 4–12. doi:10.1080/13697130500330382. PMID 16203650.
  • Wiegratz I, Kuhl H (September 2006). "Metabolic and clinical effects of progestogens". Eur J Contracept Reprod Health Care. 11 (3): 153–61. doi:10.1080/13625180600772741. PMID 17056444.
  • Stanczyk, Frank Z. (2007). "Structure –Function Relationships, Pharmacokinetics, and Potency of Orally and Parenterally Administered Progestogens": 779–798. doi:10.1016/B978-012369443-0/50067-3.
  • Sitruk-Ware R, Nath A (November 2010). "The use of newer progestins for contraception". Contraception. 82 (5): 410–7. doi:10.1016/j.contraception.2010.04.004. PMID 20933114.
  • Kuhl H (2011). "Pharmacology of progestogens" (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 8 (Special Issue 1): 157–176.
  • Lawrie TA, Helmerhorst FM, Maitra NK, Kulier R, Bloemenkamp K, Gülmezoglu AM (May 2011). "Types of progestogens in combined oral contraception: effectiveness and side-effects". Cochrane Database Syst Rev (5): CD004861. doi:10.1002/14651858.CD004861.pub2. PMID 21563141.
  • Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B (December 2011). "Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide". Contraception. 84 (6): 549–57. doi:10.1016/j.contraception.2011.04.009. PMID 22078182.
  • Moore NL, Hickey TE, Butler LM, Tilley WD (June 2012). "Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells". Mol. Cell. Endocrinol. 357 (1–2): 60–70. doi:10.1016/j.mce.2011.09.019. PMID 21945474.
  • Stanczyk FZ, Hapgood JP, Winer S, Mishell DR (April 2013). "Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects". Endocr. Rev. 34 (2): 171–208. doi:10.1210/er.2012-1008. PMC 3610676. PMID 23238854.
  • Grimes DA, Lopez LM, O'Brien PA, Raymond EG (November 2013). "Progestin-only pills for contraception". Cochrane Database Syst Rev (11): CD007541. doi:10.1002/14651858.CD007541.pub3. PMID 24226383.
  • Hapgood JP, Africander D, Louw R, Ray RM, Rohwer JM (July 2014). "Potency of progestogens used in hormonal therapy: toward understanding differential actions". J. Steroid Biochem. Mol. Biol. 142: 39–47. doi:10.1016/j.jsbmb.2013.08.001. PMID 23954501.
  • Sitruk-Ware R, El-Etr M (August 2013). "Progesterone and related progestins: potential new health benefits". Climacteric. 16 Suppl 1: 69–78. doi:10.3109/13697137.2013.802556. PMID 23647429.
  • Bińkowska M, Woroń J (June 2015). "Progestogens in menopausal hormone therapy". Prz Menopauzalny. 14 (2): 134–43. doi:10.5114/pm.2015.52154. PMC 4498031. PMID 26327902.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.